Sara Lange
Gynecologic Oncology · Merriam, KSNPI 1760616312
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,675 of the $2,552 with a category attached, or 65.6%. 33 manufacturers reported payments, led by Intuitive Surgical at 35.6% of the total. 2025 is the largest year on record at $1,198, 3.0 times the $394 reported in 2019.
Across 90 payments — averaging $28.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$908
- AstraZeneca$206
- GSK$131
- Merck$123
- AbbVie$103
- Daiichi Sankyo Inc.$79
- plus $1K from 27 others
What the payments were for
- Travel & lodging$76230%
- Food & beverage$1,67566%
- Education$1155%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $908 |
| AstraZeneca | 8 | $206 |
| GSK | 7 | $131 |
| Merck | 7 | $123 |
| AbbVie | 5 | $103 |
| Daiichi Sankyo Inc. | 4 | $79 |
| Incyte Corporation | 4 | $70 |
| Novartis | 4 | $66 |
| Sanofi | 3 | $61 |
| Johnson & Johnson | 3 | $61 |
| Clovis Oncology, Inc. | 4 | $58 |
| AVEO Pharmaceuticals, Inc. | 2 | $55 |
| Integra Lifesciences Corporation | 1 | $52 |
| Amgen | 3 | $51 |
| Coherus Oncology, Inc. | 2 | $47 |
| Exelixis Inc. | 2 | $45 |
| Foundation Medicine, Inc. | 2 | $44 |
| Mylan Institutional Inc. | 2 | $44 |
| Ipsen Biopharmaceuticals, Inc | 3 | $43 |
| Eisai Inc. | 1 | $36 |
| Blueprint Medicines Corporation | 2 | $31 |
| Tersera Therapeutics LLC | 1 | $28 |
| Geron Corporation | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Gilead | 1 | $22 |
| BD | 1 | $20 |
| Seagen Inc. | 1 | $19 |
| Acrotech Biopharma Inc. | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $18 |
| Smith+Nephew | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few gynecologic oncology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 22 | $1,003 |
| Ibuprofen | 25 | $90 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 43 | $88 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Merriam
- Brenda ShoupMerriam$1K
- Alaa ElbendaryOverland Park$5K
- Lindsay HasselwanderWestwood$3K
- Lowell ByersShawnee Mission$2K
- Jacqueline MorganWichita$2K
- Yasmin AbedinKansas City$1K
- James DelmoreWichita$852
- Michelle DudzinskiShawnee Mission$832
- Rana AlianiKansas City$194
- Thomas ChavezKansas City$119
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.